Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 139–146

doi: 10.17219/acem/38137

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Quality of Life in Patients with Type 2 Diabetes in Poland – Comparison with the General Population Using the EQ-5D Questionnaire

Dominik Golicki1,A,B,C,D,F, Marta Dudzińska2,A,B,C,E,F, Agnieszka Zwolak2,3,A,E,F, Jerzy S. Tarach2,A,E,F

1 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland

2 Department of Endocrinology, Medical University of Lublin, Poland

3 Chair of Internal Medicine and Department of Internal Medicine in Nursing, Medical University of Lublin, Poland

Abstract

Background. Complications of type 2 diabetes (T2D) lead to increased mortality and reduced quality of life (QOL).
Objectives. The aim of the study was to compare health-related quality of life (HRQoL) in Polish patients with type 2 diabetes (T2D) and in a matched sample from the general population.
Material and Methods. Data on HRQoL came from two non-interventional studies: a prospective study of patients with T2D and an EQ-5D study of Polish general population norms. The HRQoL analysis was conducted in four separate age groups: 32–44, 45–54, 55–64 and over 65 years old. We analyzed both subjective and objective assessment of HRQoL (EQ VAS and EQ-5D index) and the presence of restrictions within five dimensions of the EQ-5D descriptive part.
Results. A total of 274 patients with T2D and 214 representatives from the study of population norms were included. EQ VAS was systematically lower in diabetic patients as compared to the general population and decreased with age (68.2 vs 83.9, 62.4 vs 79.2; 54.9 vs 78.1, 50.2 vs 69.8 in consecutive age groups). A similar relationship was observed with the EQ-5D index. The largest mean differences were observed among subjects aged 55–64 years (EQ VAS: 23.2, EQ-5D index: 0.085). In three domains, i.e. self-care, usual activities and anxiety/depression, patients with diabetes who were over 45 years of age reported significantly more problems than respondents from the general population.
Conclusion. Both subjective and objective HRQoL in patients with T2D was lower than in respondents similar in age from the general population. Compared with type 2 diabetic populations from other countries, Polish patients are characterized by relatively high HRQoL objective assessment and very low subjective assessment.

Key words

diabetes mellitus, type 2, quality of life, health surveys, population surveillance.

References (25)

  1. Dudzińska M, Tarach JS, Nowakowski A: Pomiar jakości życia zależnej od zdrowia w cukrzycy. Diabetol Prakt 2011, 12, 56–64.
  2. Szelachowska M, Zonenberg A, Jakubczyk D, Zarzycka B, Popławska E, Ziętkowska C, Rybaczuk M, Kinalska I: Ocena jakości życia chorych na cukrzycę typu 1 i 2 w czasie leczenia Humalogiem. Diabetol Pol 1997, 4, 43–48.
  3. Skowron A, Turska W: Ocena jakości życia pacjentów z nadciśnieniem tętniczym i cukrzycą typu 2. Farm Pol 2008, 64, 747–752.
  4. Huk J, Nałogowska-Głośnicka K, Pawlińska-Chamra R, Fryczkowski M, Kaletka Z: Ocena porównawcza wpływu niedoborów androgenów na jakość życia mężczyzn w wieku średnim z cukrzycą i bez cukrzycy. Ann Acad Med Siles 2005, 59, 81–84.
  5. Dzieciuchowicz Ł, Pawlun M, Brzeziński J, Cerkaska K: Ocena wybranych elementów jakości życia u chorych leczonych z powodu stopy cukrzycowej. Now Lek 2002, 71, 287–291.
  6. Pacyk G, Grzeszczak W: Wpływ reformy systemu opieki zdrowotnej na jakość życia chorych na cukrzycę typu 2 leczonych w poradni diabetologicznej w latach 1999–2001. Diabetol Dośw Klin 2002, 2, 205–209.
  7. Ruprecht Z, Czaplicka I, Żmudzińska M, Bronisz A, Kłubo-Gwieździńska J, Junik R: Poprawa jakości życia w wyniku edukacji niewidomych chorych na cukrzycę. Diabetol Prakt 2003, 4, 179–183.
  8. Chełstowska M, Skibińska M, Chojnowski J, Stroiwąs-Wasilewska A, Ponikowska I: Wyniki leczenia uzdrowiskowego chorych na cukrzycę oceniane metodą kwestionariuszową jakości życia. Baln Pol 2004, 19, 73–85.
  9. Ptasiński A, Pączek L: Wpływ cukrzycy na jakość życia – ocena za pomocą kwestionariusza ADDQL w ramach praktyki lekarza rodzinnego. Med Metabol 2008, 12, 45–48.
  10. Szczęśniak G, Żmurowska B: Porównanie wpływu cukrzycy typu 2 na jakość życia kobiet i mężczyzn. Fam Med Prim Care Rev 2009, 11, 517–520.
  11. Sieradzki J, Nazar M: Intensyfikacja leczenia insuliną w Polsce. Wyniki badania podstawowych parametrów wyrównania cukrzycy i satysfakcji z leczenia w dużej populacji chorych na cukrzycę typu 2. Diabetol Prakt 2004, 5, 173–182.
  12. Pufal J, Gierach M, Pufal M, Bronisz A, Kiełbasa L, Junik R: Wpływ czynników społeczno-demograficznych i klinicznych na jakość życia chorych na cukrzycę typu 2. Diabetol Dośw Klin 2004, 4, 137–143.
  13. Brooks R, the EuroQol Group: EuroQol: the current state of play. Health Policy 1996, 37, 53–72.
  14. U.K. Prospective Diabetes Study Group: Quality of life type 2 diabetic patients is affected by complications but not by intensive polices to improve blood glucose or blood pressure control (UKPDS37). Diabetes Care 1999, 22, 1125–1136.
  15. Golicki D, Niewada M, Jakubczyk M, Wrona W, Hermanowski T: Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study. Pol Arch Med Wewn 2010, 120, 276–281.
  16. Dudzińska M, Tarach JS, Matuszek B, Kowalczyk M, Wdowiak-Barton B, Kiszczak-Bochyńska E, Nowakowski A: Evaluation of metabolic control in patients with type 2 diabetes depending on the type of hypoglycemic treatment. Diabetol Dośw Klin 2011, 11, 1–7.
  17. Dudzińska M, Kurowska M, Tarach JS, Malicka J, Nowakowski A: Accomplishment of the proper metabolic control with regard to the PDA guidelines in type 2 diabetes patients before and after introduction of insulinotherapy. Diabetol Prakt 2011, 12, 21–27.
  18. Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach JJ: Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health 2010, 13, 289–297.
  19. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS: The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med 2011, 28, 395–413.
  20. Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14, 217–230.
  21. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22, 340–349.
  22. Hayes AJ, Clarke PM, Glasziou PG, Simes RJ, Drury PL, Keech AC: Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care 2008, 31, 795–797.
  23. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M: Health-related quality of life in type 2 diabetes (TARDIS-2). Value Health 2000, 3, 47–51.
  24. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002, 25, 458–463.
  25. Johnson JA, Pickard AS, Conner-Spady B: Longitudinal changes in health-related quality of life of people with diabetes compared to those without chronic conditions. In: Badia X, ed. Proceedings of the 17th EuroQol Plenary Meeting, Pamplona, Spain, 28th–29th September, 2010, 193–206.